Notch Signaling Pathway and Endocrine Resistance in Breast Cancer

Overview

Journal Front Pharmacol

Date 2020 Jul 9

PMID 32636747

Citations 17

Authors

Jing-Wen Bai

Min Wei

Ji-Wei Li

Guo-Jun Zhang

Affiliations

Soon will be listed here.

Abstract

Nearly 70% of breast cancers express the estrogen receptor (ER) and are hormone-dependent for cell proliferation and survival. Anti-estrogen therapies with aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs) or selective estrogen receptor down regulators (SERDs) are the standard endocrine therapy approach for ER positive breast cancer patients. However, about 30% of patients receiving endocrine therapy will progress during the therapy or become endocrine resistance eventually. The intrinsic or acquired endocrine resistance has become a major obstacle for endocrine therapy. The mechanism of endocrine resistance is very complicated and recently emerging evidence indicates dysregulation of Notch signaling pathway contributes to endocrine resistance in breast cancer patients. The potential mechanisms include regulation of ER, promotion of cancer stem cell (CSC) phenotype and mesenchymal cell ratio, alteration of the local tumor microenvironment and cell cycle. This review will summarize the latest progress on the investigation of Notch signaling pathway in breast cancer endocrine resistance.

Citing Articles

17β-estradiol inhibits Notch1 activation in murine macrophage cell line RAW 264.7.

Severi P, Ascierto A, Marracino L, Ouambo Talla A, Aquila G, Martino V Mol Biol Rep. 2024; 51(1):1134.

PMID: 39514048 DOI: 10.1007/s11033-024-10058-x.

Epigenetic regulatory mechanism of macrophage polarization in diabetic wound healing (Review).

Song J, Wu Y, Chen Y, Sun X, Zhang Z Mol Med Rep. 2024; 31(1).

PMID: 39422035 PMC: 11551531. DOI: 10.3892/mmr.2024.13367.

Beauvericin Reverses Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through Regulation of Notch Signaling and Autophagy.

Patra A, Arora A, Ghosh S, Kaur Saini G ACS Pharmacol Transl Sci. 2024; 7(9):2878-2893.

PMID: 39296261 PMC: 11406685. DOI: 10.1021/acsptsci.4c00370.

Identifying Key Regulatory Genes in Drug Resistance Acquisition: Modeling Pseudotime Trajectories of Breast Cancer Single-Cell Transcriptome.

Iida K, Okada M Cancers (Basel). 2024; 16(10).

PMID: 38791962 PMC: 11119661. DOI: 10.3390/cancers16101884.

Mammalian enabled protein enhances tamoxifen sensitivity of the hormone receptor-positive breast cancer patients by suppressing the AKT signaling pathway.

He L, She C, Jiang S, Qi Z, Deng Z, Ji L Biol Direct. 2024; 19(1):21.

PMID: 38459605 PMC: 10921784. DOI: 10.1186/s13062-024-00464-3.

References

Zhang J, Zhou C, Jiang H, Liang L, Shi W, Zhang Q . ZEB1 induces ER-α promoter hypermethylation and confers antiestrogen resistance in breast cancer. Cell Death Dis. 2017; 8(4):e2732. PMC: 5477580. DOI: 10.1038/cddis.2017.154. View

McClements L, Annett S, Yakkundi A, ORourke M, Valentine A, Moustafa N . FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4. BMC Cancer. 2019; 19(1):351. PMC: 6460676. DOI: 10.1186/s12885-019-5500-0. View

Simoes B, OBrien C, Eyre R, Silva A, Yu L, Sarmiento-Castro A . Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Rep. 2015; 12(12):1968-77. PMC: 4594158. DOI: 10.1016/j.celrep.2015.08.050. View

Harrison H, Farnie G, Howell S, Rock R, Stylianou S, Brennan K . Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010; 70(2):709-18. PMC: 3442245. DOI: 10.1158/0008-5472.CAN-09-1681. View

Kopan R, Ilagan M . The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009; 137(2):216-33. PMC: 2827930. DOI: 10.1016/j.cell.2009.03.045. View

Rani A, Stebbing J, Giamas G, Murphy J . Endocrine Resistance in Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. Front Endocrinol (Lausanne). 2019; 10:245. PMC: 6543000. DOI: 10.3389/fendo.2019.00245. View

Harrison H, Simoes B, Rogerson L, Howell S, Landberg G, Clarke R . Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling. Breast Cancer Res. 2013; 15(2):R21. PMC: 3672803. DOI: 10.1186/bcr3396. View

Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar V, Perna F . Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 2016; 7:10442. PMC: 4748123. DOI: 10.1038/ncomms10442. View

Palaga T, Wongchana W, Kueanjinda P . Notch Signaling in Macrophages in the Context of Cancer Immunity. Front Immunol. 2018; 9:652. PMC: 5900058. DOI: 10.3389/fimmu.2018.00652. View

10.

Lin H, Liang Y, Dou X, Chen C, Wei X, Zeng D . Notch3 inhibits epithelial-mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis. 2018; 7(8):59. PMC: 6087713. DOI: 10.1038/s41389-018-0069-z. View

11.

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

12.

Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y . Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2019; 111(1):47-58. PMC: 6942430. DOI: 10.1111/cas.14230. View

13.

Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes R . Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res. 2014; 16(3):R62. PMC: 4095694. DOI: 10.1186/bcr3675. View

14.

Miele L, Golde T, Osborne B . Notch signaling in cancer. Curr Mol Med. 2006; 6(8):905-18. DOI: 10.2174/156652406779010830. View

15.

Scherbakov A, Andreeva O, Shatskaya V, Krasilnikov M . The relationships between snail1 and estrogen receptor signaling in breast cancer cells. J Cell Biochem. 2012; 113(6):2147-55. DOI: 10.1002/jcb.24087. View

16.

Jin Y, Kim H, Ki H, Yang I, Yang N, Lee K . Beta-catenin modulates the level and transcriptional activity of Notch1/NICD through its direct interaction. Biochim Biophys Acta. 2008; 1793(2):290-9. DOI: 10.1016/j.bbamcr.2008.10.002. View

17.

Dou X, Liang Y, Lin H, Wei X, Zhang Y, Bai J . Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α. Theranostics. 2017; 7(16):4041-4056. PMC: 5667424. DOI: 10.7150/thno.19989. View

18.

Gelsomino L, Panza S, Giordano C, Barone I, Gu G, Spina E . Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. Cancer Lett. 2018; 428:12-20. DOI: 10.1016/j.canlet.2018.04.023. View

19.

Faronato M, Nguyen V, Patten D, Lombardo Y, Steel J, Patel N . DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation. Oncotarget. 2015; 6(26):22467-79. PMC: 4673176. DOI: 10.18632/oncotarget.4164. View

20.

Sprinzak D, Lakhanpal A, LeBon L, Santat L, Fontes M, Anderson G . Cis-interactions between Notch and Delta generate mutually exclusive signalling states. Nature. 2010; 465(7294):86-90. PMC: 2886601. DOI: 10.1038/nature08959. View